WEC
KERX

Winslow Evans & Crocker’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Winslow Evans & Crocker’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-250
Closed -$3.18K – 1356
2015
Q1 		$3.18K Hold
250
– – ﹤0.01% 1111
2014
Q4 		$3.54K Hold
250
– – ﹤0.01% 1103
2014
Q3 		$3.44K Buy
+250
New +$3.83K ﹤0.01% 1175
2014
Q1 		– Sell
-1,000
Closed -$13K – 1431
2013
Q4 		$13K Buy
+1,000
New +$11.9K ﹤0.01% 835

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Winslow Evans & Crocker's KERX Position: Q2 2015 in Review

Winslow Evans & Crocker sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 250 shares — an estimated $3.18K sold.

Winslow Evans & Crocker first reported a position in KERX in Q4 2013 and held it in 4 quarters. The position peaked at $13K in Q4 2013. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • Winslow Evans & Crocker reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Winslow Evans & Crocker sold 250 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $3.18K.
  • Winslow Evans & Crocker first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 4 quarters.
  • Winslow Evans & Crocker's Keryx Biopharmaceuticals Inc position peaked at $13K in Q4 2013.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Winslow Evans & Crocker's 13F filing for Q2 2015, filed 23 Jul 2015.